NDC1 and neoplasm: However, only the cohort that was given a combination of TKT R438W and TMEM48 F169L suppressed tumor recurrence, demonstrating a tumoristatic effect on day 25, while the TKT R438W as well as the TMEM48 F169L single treatment groups showed a 2‐ and 6.6‐fold increase in tumor burden, respectively (Figure 3b and c, and Supplementary figure 5a).